Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1741 to 1750 of 1849 total matches.

Sarilumab (Kevzara) for Polymyalgia Rheumatica

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
(prednisone 15-20 mg/day or equivalent) are used for initial treatment of PMR; symptoms typically resolve ...
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab (Kevzara – Sanofi/Regeneron) for treatment of polymyalgia rheumatica (PMR) in adults who had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper. Sarilumab is the first biologic drug to be approved for treatment of PMR; it was previously approved for treatment of rheumatoid arthritis.
Med Lett Drugs Ther. 2024 May 13;66(1702):77-8   doi:10.58347/tml.2024.1702c |  Show IntroductionHide Introduction

Insect Repellents

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021  (Issue 1628)
, cover untreated skin throughout the day and night, and stay in airconditioned locations as much ...
The Centers for Disease Control and Prevention (CDC) and the Environmental Protection Agency (EPA) recommend using insect repellents to prevent infections transmitted by mosquitoes and ticks. Insect repellents applied to exposed skin should be used in conjunction with other preventive measures such as wearing pants and long-sleeved shirts and avoiding outdoor activities during peak mosquito-biting times. Mosquitoes can transmit diseasecausing pathogens, including Zika, chikungunya, dengue, West Nile, eastern equine encephalitis, and yellow fever viruses, and the malaria parasite....
Med Lett Drugs Ther. 2021 Jul 12;63(1628):109-12 |  Show IntroductionHide Introduction

Choice of Benzodiazepines

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 1988  (Issue 760)
of action are less likely to cause sedation the next day. The results of some studies suggest ...
Since The Medical Letter last reviewed the choice of benzodiazepines (Volume 23, page 41, 1981), several new drugs have been marketed and some old ones are now available generically. Most of the benzodiazepines available for oral use in the USA are listed in the table on page 28.
Med Lett Drugs Ther. 1988 Feb 26;30(760):26-8 |  Show IntroductionHide Introduction

Oat Bran for Lowering Blood Lipids

   
The Medical Letter on Drugs and Therapeutics • Dec 02, 1988  (Issue 780)
serum cholesterol concentrations. When 138 of these people added 35 to 40 grams per day of oat bran ...
Oat bran, the ground inner husk of the grain, has recently become popular as a dietary means of lowering blood lipids. It is available both separately and as a constituent of oatmeal, which is the ground product of the whole grain. Oat bran and oatmeal are available in various breakfast cereals and can also be used in baked goods, such as muffins or bread. Some of these sources are listed in the table on page 112.
Med Lett Drugs Ther. 1988 Dec 2;30(780):111-2 |  Show IntroductionHide Introduction

Salmeterol

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 1994  (Issue 921)
salmeterol regularly who use more than four inhalations a day of a short-acting β 2 agonist should see ...
Salmeterol xinafoate (Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of asthma, with or without concurrent use of inhaled corticosteroids. Salmeterol is not recommended for acute treatment of bronchospasm.
Med Lett Drugs Ther. 1994 Apr 29;36(921):37-8 |  Show IntroductionHide Introduction

Cosmetic Surgery with Lasers

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 1997  (Issue 993)
is postoperative purpura, which usually lasts for about 7 to 10 days. A retrospective study of patients with port ...
Lasers have been used in dermatology for many years. Recently, however, improvements in laser technology have led to much wider use of lasers for treatment of cosmetic skin problems. Many different types of lasers are available; the US Food and Drug Administration gives manufacturers permission to market laser systems for specific indications.
Med Lett Drugs Ther. 1997 Jan 31;39(993):10-1 |  Show IntroductionHide Introduction

Mibefradil--A New Calcium-Channel Blocker

   
The Medical Letter on Drugs and Therapeutics • Nov 07, 1997  (Issue 1013)
daily 28.65 Nisoldipine − Sular (Zeneca) 20 mg once daily 25.46 * Cost to the pharmacist for 30 days ...
Mibefradil dihydrochloride (Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as the first T-type calcium-channel blocker for treatment of hypertension and chronic stable angina.
Med Lett Drugs Ther. 1997 Nov 7;39(1013):103-5 |  Show IntroductionHide Introduction

A Pneumococcal Conjugate Vaccine for Infants and Children

   
The Medical Letter on Drugs and Therapeutics • Mar 20, 2000  (Issue 1074)
such as nephrotic syndrome, immunocompromised children (including those with HIV infection), those attending day ...
The FDA has approved a conjugate heptavalent pneumococcal vaccine for prevention of invasive pneumococcal disease in infants and children.
Med Lett Drugs Ther. 2000 Mar 20;42(1074):25-7 |  Show IntroductionHide Introduction

Tenecteplase (TNKase) for Thrombolysis

   
The Medical Letter on Drugs and Therapeutics • Nov 13, 2000  (Issue 1092)
or non-fatal stroke at 30 days was 7.1% with tenecteplase and 7.0% with alteplase. In patients ...
Tenecteplase, a recombinant variant of human tissue plasminogen activator, is now available for thrombolysis in patients with acute myocardial infarction.
Med Lett Drugs Ther. 2000 Nov 13;42(1092):106-8 |  Show IntroductionHide Introduction

Nateglinide For Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Apr 02, 2001  (Issue 1101)
Rosiglitazone − Avandia (GlaxoSmithKline) 4 to 8 mg once 72.60 * Average cost to the patient for 30 days ...
Nateglinide (Starlix), a new meglitinide oral glucose-lowering agent, has been approved by the FDA.
Med Lett Drugs Ther. 2001 Apr 2;43(1101):29-30 |  Show IntroductionHide Introduction